The World Health Organization declared an end to COVID-19 as a public health emergency in May, but it warned at the time that the virus was still causing deaths and still mutating, and the emergence of the latest subvariants of the Omicron variant of SARS-CoV-2 has triggered new vaccine activity. The major producers of COVID-19 vaccines – Pfizer Inc./BioNTech SE, Moderna, Inc. and Novavax, Inc. – are gearing up to make their vaccines against the new subvariants available by the fall, after a long trend of falling vaccine sales.
Drug Makers Gear Up For 2023-2024 COVID-19 Season With Subvariant Vaccines
Pfizer/BioNTech, Moderna, Novavax Work With Regulators
The companies are all preparing to make available vaccines targeted to Omicron XBB subvariants, with the expectation that demand in the US will be about 50 million to 100 million doses.
More from COVID-19
• By
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
• By
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
• By
Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.
• By
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
More from Scrip
• By
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.